Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of CHF5993 and CHF1535 on Lung Hyperinflation and Exercise Endurance in COPD
NCT05097014Phase 4Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Started Oct 2021; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05097014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097014.